Table 3.
Pre- and Post-PAD* Nonfatal and Fatal Events
| N (%) | In-trial PAD* event | Amlodipine vs. chlorthalidone | Lisinopril vs. chlorthalidone | ||||
|---|---|---|---|---|---|---|---|
| Chlorthalidone N = 402 | Amlodipine N = 198 | Lisinopril N = 230 | HR (95 % CI) | P value | HR (95 % CI) | P value | |
| In-trial nonfatal events | |||||||
| Pre-PAD events | |||||||
| MI | 25 (6) | 12 (6) | 14 (6) | 0.95 (0.48–1.89) | 0.885 | 1.00 (0.52–1.92) | 0.993 |
| Stroke | 17 (4) | 11 (6) | 4 (2) | 1.31 (0.61–2.79) | 0.489 | 0.41 (0.14–1.22) | 0.110 |
| Cardiac revascularization | 40 (10) | 19 (10) | 26 (11) | 0.94 (0.55–1.62) | 0.827 | 1.15 (0.70–1.89) | 0.574 |
| Heart failure | 23 (6) | 10 (5) | 16 (7) | 0.87 (0.42–1.83) | 0.720 | 1.25 (0.66–2.36) | 0.500 |
| Post-PAD events | |||||||
| MI | 48 (12) | 20 (10) | 21 (9) | 0.82 (0.48–1.40) | 0.473 | 0.74 (0.44–1.25) | 0.264 |
| Stroke | 24 (6) | 10 (5) | 13 (6) | 0.86 (0.41–1.79) | 0.684 | 0.94 (0.48–1.86) | 0.869 |
| Cardiac revascularization | 32 (8) | 22 (11) | 23 (10) | 1.39 (0.81–2.39) | 0.233 | 1.25 (0.73–2.13) | 0.422 |
| Heart failure | 39 (10) | 25 (13) | 25 (11) | 1.32 (0.79–2.18) | 0.286 | 1.08 (0.65–1.80) | 0.770 |
| Total mortality | 258 (64) | 119 (60) | 143 (62) | 0.92 (0.74–1.15) | 0.454 | 0.95 (0.77–1.18) | 0.651 |
| Cause-specific mortality†: | |||||||
| CVD | 132 (51) | 55 (46) | 70 (49) | 0.83 (0.60–1.14) | 0.252 | 0.85 (0.63–1.16) | 0.304 |
| MI | 27 (20) | 9 (16) | 15 (21) | 0.62 (0.28–1.38) | 0.242 | 0.96 (0.50–1.85) | 0.903 |
| Stroke | 13 (10) | 10 (18) | 11 (16) | 1.47 (0.64–3.36) | 0.359 | 1.47 (0.66–3.27) | 0.350 |
| Non-CVD | 120 (47) | 60 (50) | 68 (48) | 1.00 (0.73–1.38) | 0.996 | 1.04 (0.77–1.41) | 0.802 |
*Refers to documented hospitalized PAD or lower extremity PAD revascularization procedure
†Fifteen deaths with unknown cause